In short
Clinical trials are investigating Xenon in patients with aneurysmal subarachnoid hemorrhage who need ventilatory care in the intensive care unit. These studies aim to see whether Xenon can improve brain injury, neurological outcome, and survival, with safety and imaging-based effects measured in a phase 2 trial.
Key points
- Xenon is being studied in a phase 2 clinical trial for patients with aneurysmal subarachnoid hemorrhage who need ventilatory care in the intensive care unit. The study is designed to explore whether Xenon can reduce brain injury and improve neurological outcome and survival. The main outcome is a brain MRI measure called global fractional anisotropy of white matter. Researchers will compare the Xenon group with a control group. The trial is authorised and plans to enroll 160 patients.
Trial overview
The clinical trial NCT04696523 is studying Xenon in patients after aneurysmal subarachnoid hemorrhage, also called SAH. The study is authorised and is being done to explore possible neuroprotective effects, which means protection of the brain after injury.
Population and setting
This trial focuses on patients with aneurysmal subarachnoid hemorrhage who need ventilatory care in the intensive care unit. In simple words, this means the study is looking at people who are seriously ill and need breathing support and close hospital monitoring.
Study design and phase
The study is an interventional trial, which means researchers give a treatment and compare it with another study treatment. It is a Phase 2 trial, so the main goal is to learn more about whether Xenon may help and to continue checking its effects in this patient group. The planned enrollment is 160 patients.
Outcomes and endpoints
The primary endpoint is global fractional anisotropy of white matter measured by diffusion tensor imaging, which is a special MRI method. This measure is used to see how much the brain’s white matter has been damaged. The study hypothesis is that white matter damage will be less severe in patients treated with Xenon, meaning the Xenon group is expected to have a higher global fractional anisotropy score than the control group on the first MRI scan.
Interventions and comparator
The study intervention includes Xenon given by inhalation. The control treatment is CONOXIA 100% medical gas, also given by inhalation. The trial data do not provide more detail about how the groups are compared beyond these study treatments.
What this means for patients
For patients and families, this trial is asking whether Xenon can help limit brain injury after a very serious type of brain bleed. The main focus is not just survival, but also brain structure on MRI and neurological outcome, which means how well the brain and nervous system recover. Based on the available trial data, this study is early-stage research and is aimed at a critically ill hospital population.